121.50€
+
3.20€ (2.63%)
End-of-day quote: 05/16/2024
ENXTBR:UCB
UCB Competitors
| Ticker | Name | Exchange | Consensus | Price | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and | NYSE | Outperform | $770.00 | $636.99 | 0.00% | 9 | $694.32B |
| JNJ | Johnson & Johnson | NYSE | Outperform | $154.64 | $174.55 | 0.00% | 3 | $371.30B |
| MRK | Merck | NYSE | Outperform | $131.19 | $130.51 | 0.00% | 11 | $331.49B |
| ABBV | AbbVie | NYSE | Outperform | $166.42 | $178.42 | 0.00% | 11 | $290.22B |
| TMO | Thermo Fisher Scientific | NYSE | Outperform | $595.30 | $591.94 | 0.00% | 1 | $227.94B |
| NOVN | Novartis | SWX | Hold | CHF93.37 | CHF105.00 | 0.00% | 9 | CHF188.98B |
| AMGN | Amgen | NasdaqGS | Outperform | $312.47 | $303.65 | 0.00% | 8 | $168.83B |
| SAN | Sanofi | ENXTPA | Outperform | 89.17€ | 102.80€ | 0.00% | 9 | 112.81€B |
| CSL | CSL | ASX | Outperform | $280.00 | $205.51 | 0.00% | 5 | $138.67B |
| BMY | Bristol-Myers Squibb | NYSE | Hold | $44.03 | $58.15 | 0.00% | 10 | $89.42B |
| GILD | Gilead Sciences Inc | NASDAQ | Outperform | $67.72 | $87.82 | 0.00% | 14 | $84.54B |
| SHW | Sherwin Williams | NYSE | Outperform | $312.40 | $317.38 | 0.00% | 9 | $79.65B |
| LONN | Lonza Group | SWX | Buy | CHF529.20 | CHF516.89 | 0.00% | 8 | CHF38.03B |
| 4502 | Takeda Pharmaceutical Company | TSE | Outperform | ¥4.13k | ¥4.74k | 0.00% | 0 | ¥6.49T |
| PPG | PPG Industries | NYSE | Outperform | $134.44 | $159.04 | 0.00% | 1 | $31.72B |
| TEVA | Teva Pharmaceutical Industries | NYSE | Outperform | $16.29 | $11.59 | 0.00% | 9 | $18.46B |
| 4523 | Eisai | TSE | Outperform | ¥6.78k | ¥9.58k | 0.00% | 0 | ¥1.97T |
| INCY | Incyte | NasdaqGS | Outperform | $57.10 | $77.05 | 0.00% | 8 | $12.01B |
| CRDA | Croda International Plc | LSE | Outperform | £47.08 | £65.12 | 0.00% | 6 | £6.81B |
| WCH | Wacker Chemie | XTRA | Outperform | 103.15€ | 145.36€ | 0.00% | 9 | 5.00€B |
| APLS | Apellis Pharmaceuticals | NasdaqGS | Outperform | $41.31 | $79.81 | 0.00% | 3 | $5.16B |
| CLN | Clariant | SWX | Outperform | CHF14.42 | CHF16.11 | 0.00% | 6 | CHF4.67B |
| OMER | Omeros | NasdaqGM | Hold | $3.45 | $13.00 | 0.00% | 2 | $241.63M |
| XFOR | X4 Pharmaceuticals | NasdaqCM | Outperform | $0.93 | $3.26 | 0.00% | 1 | $183.05M |
| DXB | Dimerix | ASX | $0.38 | $0.00 | 0.00% | 0 | $159.38M | |
| IFRX | InflaRx N.V. | NasdaqGS | Outperform | $1.63 | $9.44 | 0.00% | 2 | $85.38M |
| BLRX | BioLineRx | TASE | - | ₪0.16 | ₪1.39 | 0.00% | 0 | ₪302.07M |
| AKTX | Akari Therapeutics, Plc | NasdaqCM | - | $1.52 | $80.00 | 0.00% | 0 | $9.39M |
